Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia

被引：0
|
作者：
Khan, Khurshid Ahmed [1 ]
Junaid, Ayesha [2 ]
Siddiqui, Nauman Saleem
Mukhtar, Khalida [3 ]
Siddiqui, Saleem [3 ]
机构：
[1] Natl Oncol Res Inst, Dept Oncol, Islamabad, Pakistan
[2] Shifa Int Hosp, Dept Pathol, Islamabad, Pakistan
[3] Shifa Int Hosp, Dept Haematol & Oncol, Islamabad, Pakistan
来源：
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN | 2008年 / 18卷 / 03期
关键词：
imatinib; chronic myeloid leukemia; bone marrow aplasia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
引用
收藏
页码：176 / 178
页数：3
相关论文
共 50 条
  • [21] Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia
    Miglino, Maurizio
    Grasso, Raffaella
    Varaldo, Riccardo
    Fugazza, Giuseppina
    Colombo, Nicoletta
    Clavio, Marino
    Canepa, Letizia
    Garuti, Anna
    Ibatici, Adalberto
    Pierri, Ivana
    Ballerini, Filippo
    Sessarego, Mario
    Gobbi, Marco
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1348 - 1351
  • [22] Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor
    Kyoko Inokura
    Yasushi Onishi
    Kenji Shimosegawa
    Yoko Okitsu
    Yuna Katsuoka
    Tohru Fujiwara
    Noriko Fukuhara
    Kenichi Ishizawa
    Hideo Harigae
    Annals of Hematology, 2012, 91 : 1825 - 1826
  • [23] BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia
    Schmidlechner, Lena
    Nagel, Inga
    Vater, Inga
    Cascorbi, Ingolf
    Kaehler, Meike
    ONCOLOGY LETTERS, 2024, 28 (03)
  • [24] Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    Marin, D
    Kaeda, JS
    Andreasson, C
    Saunders, SM
    Bua, M
    Olavarria, E
    Goldman, JM
    Apperley, JF
    CANCER, 2005, 103 (09) : 1850 - 1855
  • [25] Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia Reply
    Hehlmann, Ruediger
    Hasford, Joerg
    Pfirrmann, Markus
    Lauseker, Michael
    Saussele, Susanne
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3078 - +
  • [26] Treatment selection after imatinib resistance in chronic myeloid leukemia
    Elias Jabbour
    Jorge Cortes
    Hagop Kantarjian
    Targeted Oncology, 2009, 4 : 3 - 10
  • [27] Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment
    Deng, Zhikui
    Li, Yuanyuan
    Li, Yu-feng
    TUMORI, 2015, 101 (03) : 323 - 327
  • [28] Treatment selection after imatinib resistance in chronic myeloid leukemia
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    TARGETED ONCOLOGY, 2009, 4 (01) : 3 - 10
  • [29] Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
    Tsimberidou, AM
    Medina, J
    Cortes, J
    Rios, A
    Bonnie, G
    Faderl, S
    Kantarjian, H
    Garcia-Manero, G
    LEUKEMIA RESEARCH, 2004, 28 (06) : 657 - 660
  • [30] Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?
    Ram, Ron
    Gafter-Gvili, Anat
    Okon, Elimelech
    Pazgal, Idit
    Shpilberg, Ofer
    Raanani, Pia
    ACTA HAEMATOLOGICA, 2008, 119 (02) : 104 - 107
12345